My Pharma Reviews

Semaglutide’s India patent cliff already happened (March 20, 2026) with 50+ generics on pharmacy shelves. This is not new.

What is new is that Retatrutide just posted ~28% weight loss in Phase 3. Amgen’s antibody-peptide conjugate MariTide is racing toward monthly dosing. And the “30% tariff” story everyone’s repeating isn’t actually what’s in the Section 232 text.

In this week’s episode of My Pharma Reviews, I unpack what has changed in the GLP-1 market. I think it is the shape of the opportunity. It has splintered into at least five separate businesses that used to look like one - a) the molecule business, b) the delivery business, c) the indication business, d) the manufacturing business, and e) the trade-policy business.

Listen in.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

US President Donald Trump’s latest announcement on generic drug tariffs talks of 0% tariffs for two years (starting August 1, 2026), followed by 100% in Year 3, and 200% thereafter. This is seen as an effort to reshore generic manufacturing to the US and the phased structure gives international drugmakers a brief window to adapt before punitive import duties kick in. For the pharmacy of the world, the stakes could not be higher. With nearly 38% of India's global pharma exports ($9.7B+) bound for the US and filling almost half of all American generic prescriptions, Indian exporters face a critical structural shift.While the two-year grace period offers temporary relief, we cannot escape making hard strategic decisions on capital allocation and global supply chains. To protect market share and operating margins in thin-margin generics, Indian pharmaceutical majors will likely need to accelerate US-based manufacturing, expand CDMO partnerships, or navigate trade negotiations for exemptions. In the long run, this policy will test the agility of Indian drugmakers and reshape US healthcare economics, as absorbing high tariffs or building domestic plants could ultimately drive up drug prices for American consumers.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Morgan Stanley just called India the “blueprint” for global GLP-1 generics. The data backs it up. 26 generics, 13 companies, 6x volume growth in four months post-patent-expiry.

But their supply chain call doesn’t hold. They say there’s “no API bottleneck” coming. We’re already living the counter-example of Dr. Reddy’s semaglutide API halt this year cascaded straight through to white-label partners Torrent and USV. Aggregate Chinese capacity doesn’t protect you from a single-supplier quality event.

In this episode, I discuss the Morgan Stanley GLP-1 podcast:

* Why the $1B-by-2030 India number is a category call, not a company call - 26 generics won’t all survive the shakeout

* Why supplier concentration risk is the real story the “no bottleneck” framing misses

* Why the strategic fork isn’t semaglutide pricing, it is where you sit on tirzepatide and non-peptide oral GLP-1s

* Why peptide vs. non-peptide oral manufacturing is the most important line in the whole transcript

Listen in!

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

The global pharmaceutical landscape is facing a $300 billion patent cliff between 2026 and 2031, but the size of the prize of this value has fundamentally changed. The era of the simple generic pill is giving way to complex peptides, advanced fermentation, and biologics.

As the recent July 2026 Semaglutide API quality snag at Dr. Reddy’s demonstrates, the primary risk for manufacturers has shifted from regulatory filing hurdles to scale-up validation and manufacturing consistency. This single supply disruption has reshaped near-term market share in the GLP-1 race, underscoring that cloning a molecule is no longer enough to win.

To capture a meaningful slice of this ₹41,000 Crore incremental revenue runway, Indian pharma must pivot toward deep technical specialization. From the integrated multi-modality platforms of Cohance Lifesciences and the world-class biologics capabilities of Syngene, to the niche fermentation mastery of Concord Biotech and the massive scale of Divi’s and Aarti Drugs, the winners of this Super-Cliff will be defined by operational excellence.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

When Dr. Reddy’s Laboratories halted commercial supplies of its generic semaglutide injection due to an API scale-up impurity, it froze an outsized share of the fast-growing injectable pen volume in India, after triggering reciprocal recalls for B2B white-label partners like Torrent and USV.

While the public market has priced in the near-term financial penalty, it has largely missed the broader structural lesson that a single manufacturing node failure in Hyderabad can instantly paralyze multiple competing brands. This is not a drop in consumer demand, but a stark supply-induced stabilization that exposes the fragility of outsourced manufacturing networks.

Advanced peptide scale-up is a brutal engineering challenge, and first-mover advantage is worthless if you forfeit the market two months post-launch. As aggressive fast-followers step in to absorb stranded patients during this 90-to-120-day freeze, the competitive landscape will permanently shift before DRL bounces back in late autumn.

It is important to stop valuing the GLP-1 wave based on who files a dossier first, and start placing a massive valuation premium on vertical integration, execution robustness, and multi-vendor supply redundancies.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

India’s capital markets are sophisticated at pricing high-ROE, low-capex, cash-generative generics franchises with predictable trailing earnings. That same logic applied to a company stepping up R&D and taking on debt to fund a platform bet, appears a risk rather than optionality, producing a valuation discount precisely when conviction should command a premium.

Zydus Lifesciences, trading at a meaningful discount to peers despite genuine innovation-led capital deployment, and Wockhardt, dismissed as a struggling generics company for two decades while building what is now a landmark FDA-approved discovery pipeline, are two live, verifiable illustrations of the same underlying mispricing.

This mispricing is a real constraint on the capital allocation we have been talking about and is a real opportunity for whoever is positioned to look past it.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

This is the finale that completes the arc the series began with. The idea that launched this series was a mapping of the technology supercycle - from IBM mainframe through PC, internet, mobile, data, cloud, and chips to AGI - and the question of what the equivalent biological platform arc looks like for investors.

Episode 1 introduced the six-wave framework that answered that question at the macro level. This finale returns to that original question and answers it fully, for Wave 6 specifically - the convergence of AI, synthetic biology, BCI, and mRNA in an era where intelligence is the substrate and biology is the software.

If you listened, you would have nine episodes of context and understand the generics trap, the biologics scorecard, the CDMO qualification mechanics, the GLP-1 commodity lesson, the AI talent war, the capital allocation gap, the commercial model disintermediation, and the culture gap.

This episode does not repeat any of that. It uses all of it as the foundation for a genuinely forward-looking argument about what Wave 6 actually is, what it means in practice today, and where the wealth will concentrate.

Listen in to Episode 10 - the Series Finale - of the Bio-Health Supercycle.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

The entire commercial logic this series has examined from the MR-driven detailing model in Episode 8, the chronic refill economics implicit in the GLP-1 story in Episode 5 , assumes a patient who keeps coming back. Cell and gene therapy breaks that assumption completely. CGT is often a single infusion, priced once, intended to either cure the patient or durably control the disease, eliminating the recurring revenue stream entirely.

NexCAR19’s journey from a ₹42 lakh launch price to a ₹30 lakh price, alongside its first full year of real profitability, shows India is not just a low-cost copier of this model but an active participant proving a harder economic problem can be solved, making a curative, one-time therapy commercially sustainable at a fraction of Western pricing.

• The actual chronic-care cost stack for relapsed/refractory blood cancers in India — BMT, multi-line chemotherapy, targeted therapy — set directly against NexCAR19’s single ₹30 lakh dose

• ImmunoACT’s real financial trajectory: ₹42 lakh to ₹30 lakh pricing, ₹62 crore revenue and ₹12 crore profit in FY25, 350+ patients treated across 70 hospitals

• Why a one-time cure is a harder business model to sustain profitably than a chronic therapy, and what ImmunoACT’s manufacturing scale-up reveals about solving that problem

• What this means for Indian pharma companies whose commercial and financial architecture, examined in Episodes 7 and 8, is built entirely around recurring revenue

Listen in to Episode 9 of the Bio-Health Supercycle.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

The traditional Indian pharma commercial model was built around one assumption: that the physician is the primary, often the only, gatekeeper between a molecule and a patient, and that an army of medical representatives visiting doctors’ clinics is the most effective way to influence that gatekeeper.

That assumption is now wrong for a rapidly growing share of the market, across all three income tiers of the country simultaneously, for three different and unrelated reasons. The three-India framework from earlier analytical work is the right lens for seeing this clearly because the disintermediation is happening differently, and at different speeds, in each of the three Indias.

• The three-India commercial reality, updated with new 2025-2026 data showing which segment is being disintermediated by what, and how fast

• Government digital health infrastructure at unprecedented scale - 780 million ABHA digital health IDs, 372 million eSanjeevani teleconsultations, numbers most pharma commercial strategy decks have not internalised

• The quick-commerce entry into pharmacy (Zepto Pharmacy’s 10-minute delivery) as a genuinely new disruptive vector

• Tata 1mg and PharmEasy’s combined 55% share of online pharmacy sales, non-pharma-company platforms now sitting at the centre of the distribution chain

• What this means concretely for how Indian pharma should restructure commercial spend, threading back to the Episode 7 capital allocation lens

Listen in to Episode 8 of the Bio-Health Supercycle.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Indian pharma’s R&D intensity has been structurally stagnant for years, sitting at roughly half of global large pharma’s spend as a share of revenue and less than a third of China’s. This is not simply a function of India being a generics-focused industry, it is a capital allocation choice, made repeatedly, by boards that have other options.

Sun Pharma’s $355-416 million acquisition of Checkpoint Therapeutics shows what disciplined innovation capital allocation looks like. A single, sizeable, strategically coherent bet on a commercial-stage specialty asset, rather than either no investment at all or a scattering of small, low-conviction bets that read well in an annual report but change nothing structurally.

• Hard benchmark numbers: Alphabet’s $61 billion annual R&D spend vs. the combined R&D spend of India’s top 10 listed pharma companies

• R&D intensity comparison: global large pharma at ~23.5% of sales, China at ~17.5%, India at ~4.4-7.5%, essentially flat for years

• The Sun Pharma-Checkpoint Therapeutics deal as a worked case study in disciplined, sizeable, strategically coherent innovation capital allocation

• What boards should be asking and typically are not, connecting back to the Ternus Test introduced in Episode 2

Listen in to Episode 7 of the Bio-Health Supercycle.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com